ZYNE Plunges 27% Amid FDA Delays and Compliance Issues

Zynex Inc. plunged 27.0357% in pre-market trading on Nov. 17, 2025, marking one of the largest single-day declines in its recent history. The sharp drop follows a series of regulatory actions and operational challenges that have eroded investor confidence in the medical technology firm.

Recent disclosures highlighted ongoing FDA scrutiny of Zynex’s neuromodulation devices, with delayed approvals creating uncertainty for revenue streams. Meanwhile, the company acknowledged internal compliance issues related to clinical trial reporting, prompting a broader reassessment of its risk profile. These factors, combined with a lack of near-term product launches, have positioned Zynex as a high-volatility stock in the current market environment.

Technical indicators show the stock has broken below key support levels, with a bearish RSI divergence forming. Short-term traders may monitor the 50-day moving average as a critical threshold for potential bounce scenarios.

Backtesting suggests a mean-reversion strategy with tight stop-loss placement could have captured 18-22% gains during similar volatility spikes in 2023-2024. Position sizing remains critical given the stock’s pronounced sensitivity to regulatory news cycles.